 |
|
| Blog results | Results 1 - 10 of about 23,392 for bone marrow diseases best sites. (0.27 seconds) |
| Sorted by relevance Sort by date |
| 18 Dec 2009 BETHESDA, Md., Dec. 18, 2009-Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, ... "We now know that prolonged maintenance therapy with lenalidomide when compared to placebo will delay disease progression. This is an exciting advance in the field of multiple myeloma therapy and occurred due to the willingness of multiple myeloma patients to participate in this study and to the cooperation of ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 18 Dec 2009 by insciences Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a ... "We now know that prolonged maintenance therapy with lenalidomide when compared to placebo will delay disease progression. This is an exciting advance in the field of multiple myeloma therapy and occurred due to the willingness of ... Articles - http://insciences.org/articles.php - References [ More results from Articles ] |
| 18 Dec 2009 by CA Morrison DRUG FOR MULTIPLE MYELOMA DEMONSTRATED TO SIGNIFICANTLY EXTEND DISEASE-FREE SURVIVAL. Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, ... For more information about cancer, please visit the NCI Web site at <http://www.cancer.gov>, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). Part of the National Institutes of Health, the National Heart, Lung, ... PAXALLES - http://paxalles.blogs.com/paxalles/ |
| 10 Dec 2009 by Small Pet Supplies Researchers have for the first time performed a successful bone marrow transplant to cure sickle cell disease in adults, a feat that could expand the procedure to more of the 70000 Americans with the disease -- and possibly some other ... Emerva Networks - http://emerva.net/ |
| 22 hours ago by Henry McCusker Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. OPXA is developing TovaxinŽ, an individualized. ... (mitoxanthrone) is an immunosuppressive drug that can only be given four times per year with a lifetime limit of 8 to 12 doses,; But, CopaxoneŽ causes significant injection site reactions; while NovantroneŽ causes infections, bone marrow suppression, nausea, hair thinning, bladder infections, and mouth sores. ... Scimitar Equity Blog - http://www.scimitarequity.com/blog/ - References [ More results from Scimitar Equity Blog ] |
| 10 Nov 2009 by Kyoto University Keywords, Retinal disease. Neuroprotection Bone marrow derived stem cell. ARMD Retinitis pigmentosa. Researchers, Atsushi OTANI Nagahisa YOSHIMURA Manabu SASAHARA. Summary. Currently one out of every 4000 people are suffered from ... Kyoto University International Industry-Academi... - http://int.icc.kyoto-u.ac.jp/ |
| 5 hours ago by Daniel Chemotherapy involves poisoning the rapidly-growing cancer cells and also destroys rapidly-growing healthy cells in the bone marrow, gastro-intestinal tract etc, and can cause organ damage, like liver, kidneys, heart, lungs etc. ... A meat- based diet is acidic and it is best to eat fish, and a little chicken rather than beef or pork. Meat also contains livestock antibiotics, growth hormones and parasites, which are all harmful, especially to people with cancer. ... Favorites Bookmarks - http://www.favoritesbookmarks.com/blog/ |
| 18 Dec 2009 by Dr. Stock Pick OB PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM's patent- pending. ... The final topic covered was the discovery of biomarkers in bone marrow cells from chronic myelogenous leukemia patients that predict whether they would respond to the drug imatinib mesylate (Gleevec). ... Stock Market News & Stocks to Watch from... - http://www.straightstocks.com/ |
| 18 Dec 2009 Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer ... Ultimately, 460 patients who had adequate organ function and no evidence of progressive disease, were randomized between 90 and 100 days after transplant to receive lenalidomide or placebo. ... Latest news from our site - http://www.enewspf.com/ |
| 18 Dec 2009 by admin Dr. Goldknopf described the company's unique ability to employ Power3's blood protein biomarkers to differentially diagnose mild Alzheimer's and Parkinson's diseases, distinguish between them, distinguish from normal controls, distinguish from patients with Alzheimer's ... The final topic covered was the discovery of biomarkers in bone marrow cells from chronic myelogenous leukemia patients that predict whether they would respond to the drug imatinib mesylate (Gleevec). ... CRWE Select - http://crweselect.com/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
